22 Background: Androgen deprivation therapy (ADT) is considered standard of care in the treatment of metastatic prostate cancer (mPC). Over the past ten years, the approval of novel androgen receptor-axis-targeted therapies has changed the treatment landscape of mPC. All these novel therapies have only been approved for use in addition to ADT. Despite these new therapeutic advances, it remains...
See more from Catherine Marshall
While we talk about combining 2+ therapies, still data suggesting some men with metastatic prostate cancer are not started on ADT at all. what do you think are the barriers?